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Dr TotaroP
doi:10.1016/j.jtcvs.2007.04.031bjective: Determining the risk of patient–prosthesis mismatch after mitral valve
eplacement is still controversial. In this study, we aimed to clarify incidence and
linical implications of such a complication. The accuracy of preoperative predic-
ion of patient–prosthesis mismatch using published in vitro hemodynamic param-
ters was also investigated.
ethods: Ninety-two patients who underwent mitral valve replacement and re-
eived Carpentier–Edwards stented bioprosthesis (Edwards Lifesciences, LLC, Ir-
ine Calif) were enrolled. Hemodynamic performances were evaluated at discharge,
nd the incidence of in vivo patient–prosthesis mismatch (indexed effective orifice
rea 1.2 cm2/m2) was evaluated. Correlation between in vivo patient–prosthesis
ismatch and predicted patient–prosthesis mismatch, based on previously published
n vitro hemodynamic parameters, was also investigated.
esults: Five patients died within 30 days of the operation (5.4% mortality). Mean
rosthesis size was 29.8  2. Mean postoperative effective orifice area and indexed
ffective orifice area (2.5  0.8 cm2 and 1.5  0.4 cm2/m2, respectively) compared
avorably with those predicted in vitro (2.2  0.7 cm2 and 1.3  0.5 cm2/m2,
espectively). In the subgroup of patients receiving prosthesis size of 27 or smaller,
he difference reached statistical significance (2.47  0.83 and 1.61  0.7 for
ostoperative and predicted effective orifice areas, respectively; P  .001). Post-
perative patient–prosthesis mismatch was recorded in 8 patients (8.6%), comparing
avorably with the predicted patient–prosthesis mismatch (39% for overall popula-
ion and 80% for patients receiving prosthesis size  27). No significant correlation
etween size of prosthesis and early hemodynamic and clinical outcomes was
hown.
onclusions: In our study, stented mitral bioprostheses showed satisfactory
ostoperative hemodynamic performance, even in smaller prosthesis sizes (27
m). Risk of in vivo postoperative patient–prosthesis mismatch seems to be less
elevant than preoperative risk prediction based on in vitro data. Further studies
re needed to evaluate the potential clinical impact of mitral patient–prosthesis
ismatch.
he term patient–prosthesis mismatch (PPM) was introduced in the late 1970s
by Rahimtoola1 to describe the condition in which the effective orifice area
(EOA) of the prosthetic valve inserted into the patient was not matching the
rea of the native valve, thus causing an abnormal residual pressure gradient across
he valve with obstruction to ventricular outflow or inflow, or both. Since then,
everal studies have been designed and carried out to better clarify the cutoff value
or PPM to occur, as well as the clinical relevance of such a complication. The
ajority of these studies, however, have concentrated on PPM after aortic valve
eplacement.2-7 It is only in the recent era that the clinical consequence of mitral
PM has been considered.8
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A
CDIn this study we evaluate early postoperative hemody-
amic performance and early clinical outcomes in patients
ndergoing MVR with a stented bioprosthesis to better
larify the real risk and the early clinical relevance of mitral
PM.
atients and Methods
ata from 92 consecutive patients (male 39%, mean age 74  4
ears) who underwent MVR with a biologic prosthesis, as an
solated or combined procedure, were prospectively collected.
nly emergency operations were excluded and no patients were
xcluded on the basis of preoperative left ventricular function or
ulmonary hypertension.
Two types of Carpentier–Edwards stented bioprostheses (Peri-
ount pericardial and SAV porcine; Edwards Lifesciences, LLC,
rvine Calif) were used according to surgeon preference. Patient
haracteristics are summarized in Table 1. Preoperative and post-
perative hemodynamic performances were recorded for all survivors
nd compared with the in vitro data published by the manufacturer for
he implanted prosthesis. Incidence of postoperative PPM was eval-
ated and correlated to the predicted incidence of PPM. Finally,
ostoperative hemodynamic performance and clinical outcome were
orrelated to the size of bioprosthesis implanted.
chocardiographic Technique and Definition
ransthoracic echocardiograms performed by an experienced car-
iologist, unaware of the size of prosthesis implanted, were ob-
ained preoperatively (within 72 hours before the operation) and
ostoperatively (30 days after the operation) in all patients. As
reviously suggested,9 the postoperative mitral effective orifice
rea (MEOA) was calculated by the continuity equation method.
ndexed MEOA was calculated as MEOAIMEOA/body surface
rea. According to the definition previously published,9 mitral
atient–prosthesis mismatch was defined as MEOAI of 1.22
m2/m2 or less. Systolic pulmonary artery pressure was calculated
y adding the systolic right ventricular pressure derived from the
ricuspid regurgitation to the estimated right atrial pressure. Ac-
ording to previously published data,10 pulmonary hypertension
as defined as moderate for systolic pulmonary artery pressures of
0 mm Hg or greater and severe for systolic pulmonary artery
ressures of 60 mm Hg or greater.
urgical Technique
ll procedures were performed through a standard midline ster-
otomy and full cardiopulmonary bypass. Antegrade cold blood
ardioplegia was used as conventional myocardial protection
Abbreviations and Acronyms
EOA  effective orifice area
MEOA mitral effective orifice area
MEOAI indexed mitral effective orifice area
MVR mitral valve replacement
PPM  patient–prosthesis mismatchtrategy. The mitral valve was approached with a standard left 2
98 The Journal of Thoracic and Cardiovascular Surgery ● Septetrial incision. Native posterior leaflet or subvalvular apparatus,
r both, were preserved whenever possible. All prostheses were
mplanted with interrupted everting 2– 0 Ethibond (Ethicon Inc,
omerville, NJ) non–pledget-supported sutures (except under
pecific conditions).
tatistical Analysis
alues are expressed as mean  standard deviation. Noncontinu-
us parameters were compared by the 2 test or Fisher exact test
hen appropriate. Continuous variables were compared by the
tudent t test for paired and unpaired data when appropriate.
imple least squared linear regression was used to test the asso-
iation between continuous variables.
esults
wo patients died in the hospital (cumulative early mortal-
ty 2.5%), and 3 patients died during 30 days of surveillance
cumulative 30-day mortality 5.4%). Early postoperative
utcome (in terms of intensive care unit stay, mechanical
entilation, and cumulative hospital stay) and postoperative
emodynamic performances are summarized in Table 2A.
ostoperative hemodynamic performance measured in vivo
y transthoracic echocardiography is shown in Table 2B.
o significant differences were found comparing the two
ypes of prosthesis (mean EOAI was 1.5  0.4 and 1.4 
.5 cm2/m2 for porcine and pericardial prostheses, respec-
ively (P  .5). Average EOAI was above the limit for mitral
PM definition and EOAI less than 1.22 was obtained in only
 patients with a cumulative incidence of PPM of 8.6% (Table
ABLE 1. Patient characteristics
Age (y) 74  4
Sex
Male 36 (38)
Female 56 (62)
BSA (cm2/m2) 1.7  0.2
BMI (kg/m2) 25  5
Rhythm
Sinus 36 (38)
AF/flutter 56 (62)
LVEF
Good (EF  50%) 28 (30)
Moderate (EF 30%–50%) 48 (52)
Poor (EF  30%) 16 (18)
Pulmonary hypertension
Severe (PAP  60 mm Hg) 19 (20)
Moderate (PAP  40 mm Hg) 38 (40)
Associated procedures
MVR  AVR 21 (23)
MVR  CABG 41 (45)
SA, Body surface area; BMI, body mass index; AF, atrial fibrillation; LVEF,
eft ventricular ejection fraction; EF, ejection fraction; PAP, pulmonary
rtery pressure; MVR, mitral valve replacement; AVR, aortic valve replace-
ent; CABG, coronary artery bypass graft.B). Both postoperative MEOA and MEOAI compared
mber 2007
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A
CDavorably (although with no statistical significance) with the
redicted value based on in vitro measurement11 (Figure 1,
). Furthermore, if we consider only patients receiving
ioprosthesis sizes 25 to 27, the differences reach statistical
ignificance (Figure 1, B).
The incidence of postoperative PPM also compared fa-
orably with the predicted incidence based on the in vitro
alue. In this respect, the difference is significant either in
he overall population or in the subgroup receiving a smaller
rosthesis (Figure 2). Furthermore (Figure 3), no statisti-
ally significant correlation was found between increased
ize of implanted prosthesis and hemodynamic performance
r  0.14 for MEOA and r  0.23 for peak gradient). No
linical impact was shown in patients who experienced
PM. Postoperatively, at least moderate residual pulmonary
ypertension was shown in 41 (47%) patients (Table 2B),
ith no correlation to the size of prosthesis implanted.
iscussion
e evaluated the risk of PPM after MVR on the basis of in
ivo postoperative measurement of EOAI. Our results indi-
ABLE 2A. Early postoperative clinical outcome
30-day mortality 5 (5%)
ICU stay (d) 2.6 1.9
Ventilation time (d) 1.3 0.7
Total hospital stay (d)
Mean 14  12
Median 10
CU, Intensive care unit.
ABLE 2B. Thirty-day postoperative in vivo hemodynamic
erformance assessed by transthoracic echocardiography
MEOA (cm2) 2.4  0.9
MEOAI (cm2/m2) 1.5  0.6
Peak gradient (mm Hg) 11 8
Mean gradient (mm Hg) 5 1
PPM 8 (8.6%)
Residual pulmonary hypertension 41 (47%)
EOA, Mitral effective orifice area; MEOAI, mitral effective orifice area
Pndex; PPM, patient–prosthesis mismatch.
The Journal of Thoracicate that the predicted risk of mitral PPM, based on in vitro
easurement, significantly exceeds the real risk of PPM
fter MVR, even when small-sized bioprostheses are used.
urthermore, our study failed to show any significant cor-
elation between increased size of prosthesis implanted and
mproved early hemodynamic and clinical outcome.
PPM was first described by Rahimtoola1 in 1978 as a
linical syndrome after valve replacement with a prosthesis
oo small compared with the patient’s body surface area.
his concept has become extremely popular in the past two
ecades, and several articles have been published address-
ng this issue. The vast majority of such studies2-7 have
ocused on PPM after aortic valve replacement, inasmuch as
he prosthesis implanted in this position is generally
maller. In this respect, several aspects related to the defi-
ition,3,4 the consequences,6,7 and the prevention6,7 of PPM
ave been addressed. Several steps forward have been
ade, therefore, regarding the better understanding of aortic
PM. Conversely, regarding mitral PPM, only limited ex-
erience has been reported so far.
In our study, we aimed to evaluate the potential risk for
ncreased incidence of PPM using stented bioprostheses,
Figure 1. A, Comparison between pre-
operative predicted EOA and EOAI
based on in vitro value published by
the manufacturer and in vivo value
measured postoperatively. B, Compar-
ison between preoperative predicted
EOA and EOAI in patients receiving
size 25 and 27 prostheses. EOA, Effec-
tive orifice area; EOAI, indexed effec-
tive orifice area.
igure 2. Comparison between preoperative predicted PPM
ased on in vitro value published by the manufacturer and in vivo
PM measured postoperatively (specificity 31%, sensitivity 6%).
PM, Patient–prosthesis mismatch.
and Cardiovascular Surgery ● Volume 134, Number 3 699
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A
CDomparing early postoperative hemodynamic performance
ith the in vitro predicted hemodynamic performance. We
sed a definition of PPM based on calculated in vivo post-
perative MEOAI, which remains, despite a certain degree
f variability resulting from associate factors,12 the most
aluable parameter to evaluate PPM. To reduce prosthesis-
elated bias, we restricted the study to patients receiving
nly Edwards Lifesciences bioprostheses (pericardial or
orcine) used for many years and with a well-documented
urability and reliability.13-15
The first important finding in our study was the lack of
orrelation between increased prosthesis size and improved
ostoperative hemodynamic performance. We confirmed,
herefore, findings from Firstenberg and associates,16
ho showed a trend but not a significant correlation be-
ween increased prosthesis size and postoperative EOA after
VR with a Carpentier–Edwards Perimount bioprosthesis.
adano and coauthors17 also showed no correlation be-
ween increased size of prosthesis and improved hemody-
amic performance, but they evaluated only postoperative
ressure gradients in patients after MVR with a mechanical
rosthesis. Our experience is based on both pericardial and
orcine bioprostheses (from the same company); however,
e did not show any difference related to the type of
rosthesis, despite previous studies that suggested improved
ow geometry in pericardial compared with porcine
alves.18,19 An important finding of our study is the corre-
ation between in vivo and in vitro evaluation of hemody-
amic performance of mitral bioprostheses. Despite the
ood linear correlation that has been shown between in vivo
nd in vitro EOA for each prosthesis,7,9 the latest is usually
uperior. In our experience, postoperative in vivo EOA was,
onversely, comparable with the predicted in vitro value.
urthermore, considering only patients receiving the
maller bioprostheses (25 and 27), in vivo hemodynamic
erformances were significantly superior to those predicted
n vitro. This finding is interesting, especially considering
he opposite observation reported for aortic bioprostheses,
nd deserves further evaluation. We could only suppose that
he postimplantation behavior of a prosthesis in the mitral
osition can be influenced by different physiologic aspects,
ignificantly more than in the aortic position. m
00 The Journal of Thoracic and Cardiovascular Surgery ● SepteFavorable hemodynamic performance reflects the inci-
ence of postoperative PPM in our series, significantly
ower than the predicted risk based on in vitro measurement.
ur results, therefore, failed to confirm recent experience
rom Li and coauthors,8 who reported a high incidence of
PM after MVR (71%). At least three main characteristics
ifferentiate the series from that of Li and colleagues, how-
ver: (1) the low percentage of patients receiving a biopros-
hesis (only 16%), (2) the high percentage of patient receiv-
ng a small-sized prosthesis (52%), and (3) the time of the
chocardiographic data collection (median follow-up time
f 43 months). These specific conditions could in part
xplain the differences reported in our experience. On the
ther hand, Chan and associates (personal communication,
006) reported a 13.8% incidence of PPM (based on in vitro
ata) in 884 patients undergoing MVR mainly with mechan-
cal prostheses (75%). In our study, furthermore, the inci-
ence of PPM was not correlated to the size of bioprosthe-
is. On the basis of our experience, therefore, we would not
upport extreme efforts to implant a prosthesis bigger than
ize 25 in the patient with a small or calcified annulus. In
his case, the increased surgical risk seems unjustified by a
eal reduction of PPM incidence. It seems clear, however,
hat a homogenous method of hemodynamic performance
valuation is the first step toward a better understanding of
he real risk of mitral PPM. In our minds, postoperative
valuation of EOAI is mandatory for definition of PPM. As
ar as the clinical relevance of PPM was concerned, in our
eries only 8 patients had PPM, with no implications on
linical outcome. Despite our experience being limited to 30
ays’ follow-up, previous experiences20,21 already failed to
how clinical relevance of implantation of a “small” pros-
hesis, at least in terms of recurrence of heart failure at 5
ears’ follow-up. Also, no effect on early or late mortality
f prosthesis-related factors after MVR was shown by Fer-
andez and coauthors.22 On the other hand, Yazdanbakhsh
nd coauthors,23 using geometric valve area and a cutoff for
PM definition equal to the 10th percentile, showed signif-
cant impact of PPM on early death but not on late follow-
p. In their experience, however, the cutoff, based on a very
ow percentile, could have selected patients with “extreme”
Figure 3. Linear regression: No signif-
icant correlation is shown between
increased size of bioprosthesis im-
planted and postoperative hemodynamic
performance. Left, Postoperative pres-
sure gradient. Right, Postoperative EOA.ismatch. Concerning clinical aspects of mitral PPM, Li
mber 2007
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A
CDnd coauthors8 recently showed a significant difference in
ersistence of pulmonary hypertension (at a mean follow-up
f 43 months) in patients with mitral PPM when compared
ith those not having PPM. Even though we failed to
onfirm this finding (in our series residual pulmonary hy-
ertension was not correlated to size of prosthesis or post-
perative PPM), we have to consider that our experience is
imited to 1-month follow-up and, as a previous study
learly demonstrated,23 pulmonary artery hypertension does
ot always regress immediately after surgery. Furthermore,
s previously discussed, the group from Li and coauthors8
ncluded 71% of patients having PPM. The correlation
etween size of prosthesis implanted, postoperative PPM,
nd persistence of pulmonary hypertension therefore de-
erves further evaluation as well as the potential correlation
etween persistence of pulmonary hypertension and long-
erm clinical outcome.
onclusions
hen evaluated by postoperative EOAI, PPM after MVR
eems to be less frequent than that previously reported. In
ivo hemodynamic performances of bioprostheses can be
uperior to those calculated in vitro, especially in patients
ith smaller prostheses. Clinical relevance of mitral PPM,
oreover, has to be confirmed with more extensive studies
ased on the postoperative diagnosis of PPM.
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